These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 31941236)

  • 1. [Effect of chronic hepatitis B virus DNA negative transformation and HBsAg clearance on the occurrence of hepatocellular carcinoma].
    Zhou JL; Wang BQ; Shi YW; You H
    Zhonghua Gan Zang Bing Za Zhi; 2019 Nov; 27(11):831-833. PubMed ID: 31941236
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
    Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
    Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues.
    Yip TC; Wong GL; Chan HL; Tse YK; Lam KL; Lui GC; Wong VW
    J Hepatol; 2019 Mar; 70(3):361-370. PubMed ID: 30367899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of age and gender on risk of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Yip TC; Chan HL; Wong VW; Tse YK; Lam KL; Wong GL
    J Hepatol; 2017 Nov; 67(5):902-908. PubMed ID: 28652084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: a need for surveillance.
    Kim GA; Lee HC; Kim MJ; Ha Y; Park EJ; An J; Lee D; Shim JH; Kim KM; Lim YS
    J Hepatol; 2015 May; 62(5):1092-9. PubMed ID: 25445399
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of development of hepatocellular carcinoma in Japanese patients infected with hepatitis B virus is equivalent between genotype B and C in long term.
    Haga H; Saito T; Okumoto K; Tomita K; Katsumi T; Mizuno K; Nishina T; Watanabe H; Ueno Y
    J Viral Hepat; 2019 Jul; 26(7):866-872. PubMed ID: 30924226
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune-tolerant phase of chronic hepatitis B virus infection: A systematic review and meta-analysis.
    Liu M; Zhao T; Zhang J; Bu B; Zhang R; Xia X; Geng J
    Rev Med Virol; 2024 Jul; 34(4):e2570. PubMed ID: 38964866
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
    Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
    Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HBsAg seroclearance in chronic hepatitis B in the Chinese: virological, histological, and clinical aspects.
    Yuen MF; Wong DK; Sablon E; Tse E; Ng IO; Yuan HJ; Siu CW; Sander TJ; Bourne EJ; Hall JG; Condreay LD; Lai CL
    Hepatology; 2004 Jun; 39(6):1694-701. PubMed ID: 15185311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Yang H; Bae SH; Nam H; Lee HL; Lee SW; Yoo SH; Song MJ; Kwon JH; Nam SW; Choi JY; Yoon SK; Jang JW
    J Hepatol; 2022 Sep; 77(3):632-641. PubMed ID: 35398462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spontaneous Seroclearance of Hepatitis B Surface Antigen and Risk of Hepatocellular Carcinoma.
    Song C; Zhu J; Ge Z; Yu C; Tian T; Wang H; Han J; Shen H; Dai J; Lu J; Hu Z
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1204-1206. PubMed ID: 30114488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Implications of HBV PreS/S Mutations and the Effects of PreS2 Deletion on Mitochondria, Liver Fibrosis, and Cancer Development.
    Liang YJ; Teng W; Chen CL; Sun CP; Teng RD; Huang YH; Liang KH; Chen YW; Lin CC; Su CW; Tao MH; Wu JC
    Hepatology; 2021 Aug; 74(2):641-655. PubMed ID: 33675094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study.
    Kim MA; Kim SU; Sinn DH; Jang JW; Lim YS; Ahn SH; Shim JJ; Seo YS; Baek YH; Kim SG; Kim YS; Kim JH; Choe WH; Yim HJ; Lee HW; Kwon JH; Lee SW; Jang JY; Kim HY; Park Y; Kim GA; Yang H; Lee HA; Koh M; Lee YS; Kim M; Chang Y; Kim YJ; Yoon JH; Zoulim F; Lee JH
    Gut; 2020 Dec; 69(12):2214-2222. PubMed ID: 32209606
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Durability of hepatitis B surface antigen seroclearance and subsequent risk for hepatocellular carcinoma: A meta-analysis.
    Song A; Wang X; Lu J; Jin Y; Ma L; Hu Z; Zheng Y; Shen C; Chen X
    J Viral Hepat; 2021 Apr; 28(4):601-612. PubMed ID: 33455067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk and Risk Score Performance of Hepatocellular Carcinoma Development in Patients With Hepatitis B Surface Antigen Seroclearance.
    Park Y; Lee JH; Sinn DH; Park JY; Kim MA; Kim YJ; Yoon JH; Kim DY; Ahn SH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Clin Transl Gastroenterol; 2021 Jan; 12(1):e00290. PubMed ID: 33433118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of risk factors of hepatocellular carcinoma after hepatitis B surface antigen seroclearance.
    Kuang XJ; Jia RR; Huo RR; Yu JJ; Wang JJ; Xiang BD; Li LQ; Peng Z; Zhong JH
    J Viral Hepat; 2018 Sep; 25(9):1026-1037. PubMed ID: 29624821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High Level of Hepatitis B Core-Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load.
    Tseng TC; Liu CJ; Hsu CY; Hong CM; Su TH; Yang WT; Chen CL; Yang HC; Huang YT; Fang-Tzu Kuo S; Liu CH; Chen PJ; Chen DS; Kao JH
    Gastroenterology; 2019 Dec; 157(6):1518-1529.e3. PubMed ID: 31470004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intrahepatic distribution of hepatitis B virus antigens in patients with and without hepatocellular carcinoma.
    Safaie P; Poongkunran M; Kuang PP; Javaid A; Jacobs C; Pohlmann R; Nasser I; Lau DT
    World J Gastroenterol; 2016 Mar; 22(12):3404-11. PubMed ID: 27022222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nested case-control study: hepatocellular carcinoma risk after hepatitis B surface antigen seroclearance.
    Gounder PP; Bulkow LR; Snowball M; Negus S; Spradling PR; Simons BC; McMahon BJ
    Aliment Pharmacol Ther; 2016 Jun; 43(11):1197-207. PubMed ID: 27061300
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.